Loading color scheme

Martin Devenport, PhD, MBA

Chief Operating Officer

Dr. Devenport was previously Chief Operating Officer for OncoImmune, which was acquired by Merck in 2020. Prior to that, he was VP for Business Strategy at Amplimmune Inc., where he oversaw all project management and operational activities, as well as business development, contracts and intellectual property. Dr. Devenport is experienced with all aspects of the drug development process, including research, development, GMP manufacturing, regulatory and clinical trials, and has managed a number of biotechnology programs that reached clinical stage development in oncology and autoimmune indications.